Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UF56
UPID:
FXL17_HUMAN
Alternative names:
F-box and leucine-rich repeat protein 17; F-box only protein 13
Alternative UPACC:
Q9UF56; A1A4E3
Background:
F-box/LRR-repeat protein 17, also known as F-box and leucine-rich repeat protein 17 or F-box only protein 13, plays a crucial role in the ubiquitin-proteasome system. It acts as a substrate-recognition component of the SCF(FBXL17) E3 ubiquitin ligase complex, essential for the dimerization quality control of BTB domain-containing proteins. This protein ensures the degradation of aberrant BTB dimers, crucial for neural crest and neuronal cell differentiation and survival. Additionally, it regulates the hedgehog signaling pathway by targeting SUFU for degradation, facilitating GLI1 release for signal transduction.
Therapeutic significance:
Understanding the role of F-box/LRR-repeat protein 17 could open doors to potential therapeutic strategies.